Rahimian Aliasghar, Askari Hooman, Nabati Ali, Aminian Mahdi
Department of Clinical Biochemistry, Tehran University of Medical Sciences, Tehran, Tehran Province, Iran.
ScientificWorldJournal. 2025 Jul 3;2025:9976167. doi: 10.1155/tswj/9976167. eCollection 2025.
The outbreak of COVID-19 took the world by surprise and dealt a serious blow to the global economy. Even today, few drugs against SARS-CoV-2 infection have been proven useful, and repurposing existing antiviral therapies remains a major research area in the treatment of the disease. During previous viral outbreaks, therapies using convalescent plasma and related products have repeatedly been used as empirical approaches. Rapid preparation of convalescent plasma and hyperimmune globulins (hIVIGs) makes these two treatment options useful in dealing with outbreaks of emerging diseases. The current study presents a systematic roadmap concerning the guidelines, criteria, and regulations involved in plasma transfusion and the preparation of hIVIGs applicable to possible future viral outbreaks.
新型冠状病毒肺炎（COVID-19）的爆发令世界猝不及防，并给全球经济带来了沉重打击。即便在今天，经证实有效的抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的药物仍寥寥无几，重新利用现有的抗病毒疗法仍是该疾病治疗领域的一个主要研究方向。在以往的病毒爆发期间，使用康复期血浆及相关制品的疗法曾多次被用作经验性治疗手段。快速制备康复期血浆和高效价免疫球蛋白（hIVIG）使这两种治疗选择在应对新发疾病爆发时颇为有用。本研究提出了一个系统的路线图，涉及适用于未来可能出现的病毒爆发的血浆输注及hIVIG制备的指南、标准和规范。
